Manuscripts and Publications
Filters: Keyword is Anti-HIV Agents [Clear All Filters]
.
2021. Models of HIV Pre-Exposure Prophylaxis Care Used in Title X Family Planning Clinics in the Southern U.S.. J Adolesc Health. 68(3):480-487.
.
2021. Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use.. Clin Infect Dis. 72(3):386-387.
.
2021. Pre-exposure Prophylaxis Implementation in Family Planning Services Across the Southern United States: Findings from a Survey Among Staff, Providers and Administrators Working in Title X-Funded Clinics.. AIDS Behav. 25(6):1901-1912.
.
2021. A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men.. AIDS Behav. 25(7):2054-2070.
.
2021. A Tale of Two Cities: Exploring the Role of Race/Ethnicity and Geographic Setting on PrEP Use Among Adolescent Cisgender MSM.. AIDS Behav. 25(1):139-147.
.
2020. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
.
2020. Comparative Effectiveness of Community-Based vs Clinic-Based Healthy Choices Motivational Intervention to Improve Health Behaviors Among Youth Living With HIV: A Randomized Clinical Trial.. JAMA Netw Open. 3(8):e2014650.
.
2020. Crystal Clear with Active Visualization: Understanding Medication Adherence Among Youth Living with HIV.. AIDS Behav. 24(4):1207-1211.
.
2020. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.. Ann Epidemiol. 44:16-30.
.
2020. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.. Ann Epidemiol. 45:24-31.e3.
.
2020. Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions.. AIDS Behav. 24(9):2637-2649.
.
2019. Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.. J Acquir Immune Defic Syndr. 80(2):160-165.
.
2019. Implementation Strategies to Increase PrEP Uptake in the South.. Curr HIV/AIDS Rep. 16(4):259-269.
.
2019. A Multi-Site Study of Social Cognitive Factors Related to Adherence Among Youth Living With HIV in the New Era of Antiretroviral Medication.. J Pediatr Psychol. 44(1):98-109.
.
2019. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
.
2019. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
.
2018. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 66(2):213-219.
.
2018. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
.
2018. Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
.
2017. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
.
2017. HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
.
2017. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
.
2017. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
.
2017. Understanding Care Linkage and Engagement Across 15 Adolescent Clinics: Provider Perspectives and Implications for Newly HIV-Infected Youth.. AIDS Educ Prev. 29(2):93-104.
.
2016. Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.. AIDS Patient Care STDS. 30(7):339-48.
.
2016. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
.
2016. Behavioral and Health Outcomes for HIV+ Young Transgender Women (YTW) Linked To and Engaged in Medical Care.. LGBT Health. 3(2):162-7.
.
2016. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
.
2016. Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
.
2016. Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.
.
2015. Acceptability and Feasibility of a Cell Phone Support Intervention for Youth Living with HIV with Nonadherence to Antiretroviral Therapy.. AIDS Patient Care STDS. 29(6):338-45.
.
2015. Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.. Pediatr Infect Dis J. 34(4):406-8.
.
2015. Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
.
2015. Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
.
2014. The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial.. AIDS Behav. 18(4):686-96.
.
2014. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
.
2013. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
.
2013. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV.. AIDS Behav. 17(1):86-93.
.
2012. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care.. AIDS Patient Care STDS. 26(2):108-15.
.
2012. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
.
2009. Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors.. Arch Pediatr Adolesc Med. 163(12):1092-8.
.
2009. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
.
2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.